Engineered mRNA sequences and their uses
By designing engineered mRNAs containing RPS27A 5′UTR and 3′UTR, combined with chemical modification, the problems of protein expression instability and immunogenicity in mRNA treatment were solved, and efficient protein expression and stability improvement were achieved.
Patent Information
- Application Number
- CN202080038786.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-03-25
- Filing Date
- 2020-03-25
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2040-03-25
AI Technical Summary
In existing mRNA treatments, the protein expression levels of delivered mRNA vary greatly, making it difficult to effectively improve, and exogenous proteins are immunogenic at high doses, resulting in poor efficacy.
An engineered mRNA containing the 5′ untranslated region (5′UTR) and 3′ untranslated region (3′UTR) of RPS27A was designed to improve the expression efficiency and half-life of mRNA in combination with chemically modified Nucleotide, enhances protein expression.
It significantly improves protein expression levels, reduces immune response, improves efficacy, and enhances mRNA stability and intracellular expression efficiency.
Smart Images

Figure CN114207134B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 823,215, filed March 25, 2019, which is expressly incorporated herein by reference.
[0003] Statement Regarding Federally Sponsored Research
[0004] This invention was made with government support under Grant No. R35GM119679 awarded by the National Institutes of Health. The government has certain rights in this invention. Technical Field
[0005] The present disclosure relates to a series of engineered mRNA sequences and methods of using the same to improve protein expression. Background Art
[0006] Messenger RNA (mRNA) is a crucial mediator and regulator of gene expression from DNA into proteins. All proteins in living organisms are produced within cells using mRNA as a blueprint in a process called translation. To balance the biological functions of various proteins, the intracellular process of protein production from mRNA is meticulously regulated.
[0007] Messenger RNA is a long polynucleotide chain composed of several major segments from 5' to 3': the cap, 5' untranslated region (5'UTR), coding region, 3' untranslated region (3'UTR), and tail. The cap at the 5' end is involved in recruiting the translation initiation complex, including the ribosome. The coding region determines what protein will be produced after translation. The 5'UTR and 3'UTR are key elements in regulating the expression levels of the encoded protein from the mRNA. Their mechanism of action largely relies on the interaction between their unique nucleotide sequences and the corresponding RNA binding proteins (RBPs) that recognize these sequences. The half-life and expression efficiency of mRNA are generally regulated by various RBPs that bind to the 5'UTR and 3'UTR. Most mRNAs in mammalian cells contain a polyadenylic acid (polyA) tail at their 3' end. The polyA tail contributes to the stability of the mRNA chain by conferring resistance to the 3' to 5' decay pathway, thereby extending the mRNA half-life. The poly A tail has also been found to wrap back around the 5' end of the mRNA and play a role in translation initiation.
[0008] Many diseases arise from errors in cellular protein synthesis, resulting in insufficient functional proteins or mutated harmful proteins. Traditional protein therapies manufacture the desired proteins in other organisms and deliver them directly into cells to supplement or correct missing cellular functions. However, many delivered proteins are insufficient at low doses and are immunogenic at high doses due to their exogenous nature.
[0009] An emerging field of mRNA therapy involves synthesizing protein-encoding mRNA in the laboratory through a process called in vitro transcription and delivering this mRNA into cells. The desired protein encoded by the mRNA can be produced by the protein synthesis machinery within the cell. However, the protein expression levels of the delivered mRNA vary widely. What is needed is a method for improving the expression efficiency and half-life of the delivered mRNA. Summary of the Invention
[0010] Disclosed herein are a series of engineered mRNAs and methods for improving protein expression.
[0011] In some aspects, disclosed herein is an engineered mRNA comprising: a first nucleic acid sequence comprising a RPS27A 5' untranslated region (5'UTR) sequence or an engineered 5' untranslated region (5'UTR) sequence; a second nucleic acid sequence comprising a heterologous nucleic acid sequence; and a third nucleic acid sequence comprising a RPS27A 3' untranslated region (3'UTR) sequence.
[0012] In some embodiments, the RPS27A 5'UTR sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, or SEQ ID NO: 11.
[0013] In some embodiments, the heterologous nucleic acid sequence encodes a target protein. In some embodiments, the target protein is any protein of interest (POI).
[0014] In some embodiments, the target protein is an immunotherapy protein. In some embodiments, the target protein is a co-stimulatory molecule. In some embodiments, the target protein is a genome editing enzyme or a nuclease. In some embodiments, the target protein is used in protein replacement therapy.
[0015] In some embodiments, the target protein comprises a fluorescent protein. In some embodiments, the target protein is fused to a fluorescent protein. In one embodiment, the fluorescent protein is mCherry (mCh). In some embodiments, the fluorescent protein is GFP or YFP.
[0016] In some embodiments, the target protein comprises a viral protein. In some embodiments, the viral protein is a COVID-19 protein.
[0017] In some embodiments, the RPS27A 3'UTR sequence is selected from the group consisting of SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:87, SEQ ID NO:89, or SEQ ID NO:91.
[0018] In some embodiments, the engineered mRNA of any of the aforementioned aspects comprises an RNA sequence selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, or SEQ ID NO: 40.
[0019] In some embodiments, the engineered mRNA of any of the preceding aspects comprises an RNA sequence selected from the group consisting of SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97.
[0020] In some embodiments, the mRNA comprises at least one chemically modified nucleotide. In some embodiments, the at least one chemically modified nucleotide is a chemically modified nucleobase. In some embodiments, the chemically modified nucleobase is pseudouridine.
[0021] In some aspects, disclosed herein is a vector comprising the engineered mRNA of any of the foregoing aspects. In some embodiments, a cell comprises the vector of any of the foregoing aspects.
[0022] In some aspects, disclosed herein is a method of increasing protein expression, comprising the steps of introducing into a cell an engineered mRNA comprising: a first nucleic acid sequence comprising a RPS27A 5′UTR sequence; a second nucleic acid sequence comprising a heterologous nucleic acid sequence; and a third nucleic acid sequence comprising a RPS27A 3′UTR sequence.
[0023] In some embodiments, the RPS27A 5'UTR sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, or SEQ ID NO: 11.
[0024] In some embodiments, the heterologous nucleic acid sequence encodes a target protein. In some embodiments, the target protein is any protein of interest (POI).
[0025] In some embodiments, the target protein comprises a fluorescent protein. In some embodiments, the target protein is fused to a fluorescent protein. In one embodiment, the fluorescent protein is mCherry (mCh). In some embodiments, the fluorescent protein is GFP or YFP.
[0026] In some embodiments, the target protein comprises a viral protein. In some embodiments, the viral protein is a COVID-19 protein.
[0027] In some embodiments, the RPS27A 3'UTR sequence is selected from the group consisting of SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:87, SEQ ID NO:89, or SEQ ID NO:91.
[0028] In some embodiments, the engineered mRNA comprises an RNA sequence selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, or SEQ ID NO: 40.
[0029] In some embodiments, the engineered mRNA comprises an RNA sequence selected from the group consisting of SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97.
[0030] In some aspects, disclosed herein is an engineered mRNA comprising: a first nucleic acid sequence comprising an engineered 5′ untranslated region (5′UTR) sequence; a second nucleic acid sequence comprising a heterologous nucleic acid sequence; and a third nucleic acid sequence comprising a RPS27A 3′ untranslated region (3′UTR) sequence.
[0031] In some embodiments, the engineered 5′UTR sequence is selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, or SEQ ID NO: 86. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several aspects described below.
[0033] Figure 1A to Figure 1B luciferase mRNA with and without modified 5′UTR and 3′UTR from mouse ribosomal protein S27a gene in A549 cells ( Figure 1A ) and Hep3B cells ( Figure 1B AG+G, AG+G without 3UTR, and CYBA are control luciferase mRNAs with the same coding sequence as the other engineered mRNAs.
[0034] Figures 2A to 2C The expression of eGFP mRNA with and without modified 5′UTR and 3′UTR from mouse ribosomal protein S27a gene in A549 cells ( Figure 2A ), Hep3B cells ( Figure 2B ) and 293T cells ( Figure 2C ) in vitro expression.
[0035] Figure 3 Shown is the in vitro expression of luciferase mRNA engineered with 5UTR-18 and 3UTR-1 with or without pseudouridine modification in A549 cells.
[0036] Figures 4A to 4B The expression of pseudouridine-modified luciferase mRNAs engineered with 5UTR-22+3UTR-1 and 5UTR-23+3UTR-1 in Hep3B cells ( Figure 4A ) and A549 cells ( Figure 4B ) in vitro expression.
[0037] Figure 5 In vivo imaging of organelles targeted by eGFP / mCherry mRNA with 5'UTR and 3'UTR sequences disclosed herein or by commercially available imaging probes using living Hep3B cells is shown.
[0038] Figures 6A to 6B The expression of firefly luciferase mRNA with 5'UTR consisting of 10nt (5UTR-12), 30nt (5UTR-14), 50nt (5UTR-16), 70nt (5UTR-18) or 90nt (5UTR-24) in mammalian cells is shown. Figure 6A ) and 293T cells ( Figure 6B ) results.
[0039] 7A to 7B The microRNA target site located in the 5′UTR was removed to enhance mRNA expression. Figure 7A ) and 293T cells ( Figure 7B ) results.
[0040] Figures 8A to 8B The figure shows that an additional functional RNA motif is attached to the 3′ end of 3UTR-1 to enhance mRNA expression. Figure 8A ) and 293T cells ( Figure 8B ) results. DETAILED DESCRIPTION
[0041] Disclosed herein are a series of engineered mRNAs comprising modified portions of the RPS27A 5'UTR and the RPS27A 3'UTR, and methods for improving protein expression. Also disclosed herein are a series of engineered mRNAs comprising engineered (non-naturally occurring) 5'UTR sequences, and methods for improving protein expression.
[0042] Reference will now be made in detail to embodiments of the present invention, examples of which are illustrated in the accompanying drawings and examples. However, this invention may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.
[0043] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention belongs. As used herein, the term "include" and its variations are used synonymously with the term "comprise" and its variations and are open, non-restrictive terms. Although the terms "comprise" and "include" are used herein to describe various embodiments, the terms "consisting essentially of" and "consisting of" may be used in place of "comprise" and "include" to provide more specific embodiments, and are also disclosed. Unless the context clearly indicates otherwise, as used in this disclosure and the appended claims, the singular forms "a", "an", "the" include plural referents.
[0044] The following definitions are provided to provide a comprehensive understanding of the terms used in this specification.
[0045] the term
[0046] As used herein, the term "nucleic acid" refers to a polymer composed of nucleotides (eg, deoxyribonucleotides or ribonucleotides).
[0047] As used herein, the terms "ribonucleic acid" and "RNA" refer to a polymer composed of ribonucleotides.
[0048] The term "polynucleotide" refers to a single-stranded or double-stranded polymer composed of nucleotide monomers.
[0049] The term "polypeptide" refers to a compound composed of a single chain of D-amino acids or L-amino acids or a mixture of D-amino acids and L-amino acids joined by peptide bonds.
[0050] The term "target protein" refers to a protein or polypeptide expressed by a given engineered mRNA. Target proteins can be naturally occurring or artificial molecules. Furthermore, they can be used in their unaltered state or as aggregates with other substances.
[0051] The term "complementary" refers to the topological compatibility or matching together of the interaction surfaces of the probe molecule and its target. Thus, a target and its probe can be described as complementary, and furthermore, the contact surface properties are complementary to each other.
[0052] The term "hybridization" refers to the process of establishing non-covalent, sequence-specific interactions between two or more complementary nucleic acid strands to form a single hybrid, which in the case of two strands is called a duplex.
[0053] The term "annealing" refers to the process by which a single-stranded nucleic acid sequence pairs with a complementary sequence through hydrogen bonds to form a double-stranded nucleic acid sequence, including the reformation (renaturation) of complementary chains separated by heat (thermal denaturation).
[0054] The term "melting" refers to the denaturation of a double-stranded nucleic acid sequence due to high temperature, resulting in the separation of the double strand into two single strands by breaking hydrogen bonds between the strands.
[0055] The term "promoter" or "regulatory element" refers to a region or sequence determinant that is located upstream or downstream of the start of transcription and that participates in identifying and binding RNA polymerase and other proteins to initiate transcription. Promoters need not be of bacterial origin, for example, promoters derived from viruses or other organisms can be used in the compositions, systems or methods described herein. The term "regulatory element" is intended to include promoters, enhancers, internal ribosomal entry sites (IRES) and other expression control elements (e.g., transcription termination signals, such as polyadenylation signals and poly-U sequences). For example, such regulatory elements are described in Goeddel, Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif. (1990). Regulatory elements include regulatory elements that direct constitutive expression of nucleotide sequences in many types of host cells and regulatory elements (e.g., tissue-specific regulatory sequences) that direct expression of nucleotide sequences only in certain host cells. Tissue-specific promoters can direct expression primarily in a desired tissue of interest, such as muscle, neurons, bone, skin, blood, a specific organ (e.g., liver, pancreas), or a specific cell type (e.g., lymphocytes). Regulatory elements can also direct expression in a time-dependent manner, such as in a cell cycle-dependent or developmental stage-dependent manner, which may or may not be tissue- or cell-type-specific. In some embodiments, the vector comprises one or more pol III promoters (e.g., 1, 2, 3, 4, 5, or more pol I promoters), one or more pol II promoters (e.g., 1, 2, 3, 4, 5, or more pol II promoters), one or more pol I promoters (e.g., 1, 2, 3, 4, 5, or more pol I promoters), or a combination thereof. Examples of pol III promoters include, but are not limited to, the U6 promoter and the H1 promoter. Examples of pol II promoters include, but are not limited to, the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with a RSV enhancer), the cytomegalovirus (CMV) promoter (optionally with a CMV enhancer) [see, e.g., Boshart et al., Cell, 41:521-530 (1985)], the SV40 promoter, the dihydrofolate reductase promoter, the β-actin promoter, the phosphoglycerol kinase (PGK) promoter, and the EF1α promoter.The term "regulatory element" also encompasses enhancer elements such as WPRE; CMV enhancer; R-U5' segment in the LTR of HTLV-I (Mol. Cell. Biol., Vol. 8(1), pp. 466-472, 1988); SV40 enhancer; and the intron sequence between exon 2 and exon 3 of rabbit β-globin (Proc. Natl. Acad. Sci. USA., Vol. 78(3), pp. 1527-31, 1981). One skilled in the art will appreciate that the design of the expression vector may depend on factors such as the choice of the host cell to be transformed, the desired expression level, and the like.
[0056] The term "recombinant" refers to a nucleic acid (e.g., a polynucleotide) manipulated by a person or a copy or complement of a nucleic acid (e.g., a polynucleotide) manipulated by a person, or, if a protein is involved (i.e., a "recombinant protein"), to a protein encoded by a recombinant nucleic acid (e.g., a polynucleotide). In an embodiment, a recombinant expression cassette comprising a promoter operably linked to a second nucleic acid (e.g., a polynucleotide) may include a promoter that is heterologous to a second nucleic acid (e.g., a polynucleotide) as a result of human manipulation (e.g., by methods described in Sambrook et al., Molecular Cloning-A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, (1989) or Current Protocols in Molecular Biology, Vols. 1-3, John Wiley & Sons, Inc. (1994-1998)). In another example, a recombinant expression cassette may include nucleic acids (e.g., polynucleotides) that are combined in a manner that is highly unlikely to be found in nature. For example, human manipulated restriction sites or plasmid vector sequences can flank the promoter or separate the promoter from the second nucleic acid (e.g., polynucleotide). Those skilled in the art will recognize that nucleic acids (e.g., polynucleotides) can be manipulated in a variety of ways and are not limited to the above examples.
[0057] "Encoding" refers to the inherent property of a specific nucleotide sequence in a polynucleotide (such as a gene, cDNA or mRNA) to serve as a template for the synthesis of other polymers and macromolecules in biological processes, said other polymers and macromolecules having a defined nucleotide sequence (i.e., rRNA, tRNA and mRNA) or a defined amino acid sequence and the resulting biological properties.
[0058] The term "expression cassette" or "vector" refers to a nucleic acid construct that, when introduced into a host cell, results in transcription and / or translation of an RNA or polypeptide, respectively. In embodiments, an expression cassette comprising a promoter operably connected to a second nucleic acid (e.g., a polynucleotide) may include a promoter heterologous to the second nucleic acid (e.g., a polynucleotide) as a result of human manipulation (e.g., by methods described in Sambrook et al., Molecular Cloning-A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, (1989) or Current Protocols in Molecular Biology Vol. 1-3, John Wiley & Sons, Inc. (1994-1998)). In some embodiments, an expression cassette comprising a terminator (or termination sequence) operably connected to a second nucleic acid (e.g., a polynucleotide) may include a terminator heterologous to the second nucleic acid (e.g., a polynucleotide) as a result of human manipulation. In some embodiments, as a result of human manipulation, the expression cassette comprises a promoter operably linked to a second nucleic acid (e.g., a polynucleotide) and a terminator operably linked to the second nucleic acid (e.g., a polynucleotide). In some embodiments, the expression cassette comprises an endogenous promoter. In some embodiments, the expression cassette comprises an endogenous terminator. In some embodiments, the expression cassette comprises a synthetic (or non-natural) promoter. In some embodiments, the expression cassette comprises a synthetic (or non-natural) terminator.
[0059] "Fragments", whether or not attached to other sequences, may also include insertions, deletions, substitutions, or other selected modifications of specific regions or specific amino acid residues, provided that the activity of the fragment is not significantly altered or impaired compared to the unmodified peptide or protein. These modifications may provide additional properties, such as removing or adding amino acids capable of disulfide bonding, extending its biological lifespan, altering its secretion characteristics, etc.
[0060] "Increase" can refer to any change that results in a higher level of gene expression, protein expression, symptom quantity, disease, composition, condition, or activity. A substance is also understood to increase the level of a gene, protein, composition, or condition quantity when the level of the gene, protein, composition, or condition quantity is greater / higher than the level of the gene, protein, composition, or condition quantity in the absence of the substance. In addition, for example, an increase can be a change in the symptoms of a disease such that the symptoms are less than previously observed. An increase can be any individual increase, median increase, or average increase in a condition, symptom, activity, or composition that is statistically significant. Thus, an increase can be an increase of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, as long as the increase is statistically significant.
[0061] "Reduction" can refer to any change that causes lower levels of gene expression, protein expression, symptom amount, disease, composition, condition or activity. When the level of a gene, protein, composition or condition amount is less / lower relative to the output of the level of the gene, protein, composition or condition amount when there is no substance, the substance is also understood to be the level that reduces the gene, protein, composition or condition amount. Reduction can be any individual reduction, median reduction or average reduction of the statistically significant amount of a condition, symptom, activity, or composition. Therefore, reduction can be a reduction of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%, as long as the reduction is statistically significant.
[0062] In the context of two or more nucleic acid or polypeptide sequences, the terms "identical" or "percent identity" refer to two or more sequences or subsequences that are identical or have a specified percentage of amino acid residues or nucleotides that are identical (i.e., about 60% identity over the specified region, preferably 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100%, 101%, 102%, 103%, 104%, 105%, 106%, 107%, 108%, 109%, 110%, 111%, 112%, 113%, 114%, 115%, 116%, 117%, 118%, 119%, 120%, 121%, 122%, 123%, 124%, 125%, 126%, 127%, 128%, 129%, 130%, 131%, 132%, 133%, 134%, 135 %, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher identity), as measured using BLAST or BLAST 2.0 sequence comparison algorithms with the following default parameters or by manual alignment and visual inspection (see, for example, NCBI website etc.). Such sequences are referred to as "substantially identical". This definition also relates to or may be applicable to the supplementation of test sequences. This definition also includes sequences with deletions and / or additions, and sequences with substitutions. As described below, preferred algorithms may consider rooms etc. Preferably, identity is present in a region that is at least about 10 amino acids or 20 nucleotides in length, or more preferably is present in a region that is 10 to 50 amino acids or 20 to 50 nucleotides in length. As used herein, amino acid sequence identity percentage (%) is defined as the percentage of the amino acid identical with the amino acid in the reference sequence in the candidate sequence after aligning the sequences and introducing a room (if necessary) to achieve maximum sequence identity percentage. The comparison for measuring sequence identity percentage can be achieved in a variety of ways within the scope of the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR) software. Suitable parameters for measuring the comparison can be determined by known methods, including any algorithm required for maximum comparison over the full length of the compared sequences.
[0063] For sequence comparison, usually a sequence serves as a reference sequence, and a test sequence is compared with the reference sequence. When using a sequence comparison algorithm, the test sequence and the reference sequence are input into a computer, and subsequence coordinates (if necessary) and sequence algorithm program parameters are specified. Preferably, default program parameters can be used, or alternative parameters can be specified. The sequence comparison algorithm then calculates the sequence identity percentage of the test sequence relative to the reference sequence based on the program parameters.
[0064] An example of an algorithm suitable for determining percent sequence identity and sequence similarity is the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1977) Nuc. Acids Res. 25:3389-3402 and Altschul et al. (1990) J. Mol. Biol. 215:403-410, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http: / / www.ncbi.nlm.nih.gov / ). The algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is called the neighborhood word score threshold (Altschul et al. (1990) J. Mol. Biol. 215:403-410). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. As long as the cumulative alignment score can be increased, the word hits are extended in both directions along each sequence. For nucleotide sequences, the cumulative score is calculated using the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatched residues; always <0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. The expansion of the word hit in each direction stops when: the cumulative alignment score drops by an amount X from its maximum achieved value; the cumulative score becomes zero or lower due to the accumulation of one or more negative-scoring residue alignments; or the end of any sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) defaults to using a word length (W) of 11, an expectation (E) of 10, M=5, N=-4, and a comparison of two chains. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915) alignment (B) of 50, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands.
[0065] The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90: 5873-5787). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01.
[0066] The term "codon optimized" when referring to a gene or coding region of a nucleic acid molecule used to transform a variety of hosts refers to changing the codons in the gene or coding region of a polynucleic acid molecule to reflect the typical codon usage of a selected organism without changing the polypeptide encoded by the DNA. Such optimization includes replacing at least one, more than one, or a large number of codons with one or more codons more frequently used in the genes of the selected organism.
[0067] When a nucleic acid is placed in a functional relationship with another nucleic acid sequence, the nucleic acid is "operably linked". For example, if the DNA of a presequence or secretory leader sequence is expressed as a preprotein that participates in the secretion of a polypeptide, the DNA is operably linked to the DNA of the polypeptide; if a promoter or enhancer affects the transcription of the sequence, the promoter or enhancer is operably linked to the coding sequence; or if a ribosome binding site is positioned to promote translation, the ribosome binding site is operably linked to the coding sequence. Generally, "operably linked" means that the DNA sequences being linked are close to each other and, in the case of a secretory leader sequence, are continuous and in the reading phase. However, operably linked nucleic acids (such as enhancers and coding sequences) do not have to be continuous. Connection is accomplished by connecting at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adapters or joints are used according to conventional practice. In an embodiment, when a promoter is capable of affecting (e.g., regulating relative to the absence of a promoter) the expression of a protein from a coding sequence, the promoter is operably linked to the coding sequence (i.e., the coding sequence is under the transcriptional control of the promoter).
[0068] The term "nucleobase" refers to the portion of a nucleotide that has Watson / Crick base pairing functionality. The most common naturally occurring nucleobases, adenine (A), guanine (G), uracil (U), cytosine (C), and thymine (T), have hydrogen bonding functionality that allows one nucleic acid strand to bind to another in a sequence-specific manner.
[0069] As used throughout, "subject" (or "host") refers to an individual. Thus, a "subject" can include, for example, domesticated animals (e.g., cats, dogs, etc.), livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), laboratory animals (e.g., mice, rabbits, rats, guinea pigs, etc.), mammals, non-human mammals, primates, non-human primates, rodents, birds, reptiles, amphibians, fish, and any other animal. A subject can be a mammal, such as a primate or a human.
[0070] As used herein, the term "about" when referring to a measurable value such as an amount, a percentage, etc., is intended to encompass variations of ±20%, ±10%, ±5%, or ±1% relative to the measurable value.
[0071] A nucleic acid sequence is "heterologous" to a second nucleic acid sequence if the sequence originates from a foreign species or, if from the same species, has been modified from its original form by human action. For example, a promoter operably linked to a heterologous coding sequence means that the coding sequence is from a species different from the species from which the promoter is derived, or, if from the same species, the coding sequence is not a naturally occurring allelic variant.
[0072] As used herein, the term "treatment " and grammatical variations thereof include partially or completely delaying, alleviating, relieving or reducing the intensity of one or more associated symptoms of a disease or condition, and / or alleviating, alleviating or hindering one or more causes of a disease or condition. Treatments according to the present invention may be applied preventively, prophylactically, palliatively or remedially. Prophylactic treatment is administered to a subject before the onset of disease, during the early stages of disease, or after established development of cancer. Prophylactic administration may be performed from several days to several years before symptoms of infection are manifested.
[0073] As used herein, the term "vaccine" refers to a formulation containing the engineered mRNA of the present invention, which is in a form that can be administered to a subject and induces a protective immune response sufficient to induce immunity to prevent and / or improve infection and / or alleviate at least one symptom of infection and / or enhance the efficacy of another dose of the vaccine. Typically, the vaccine comprises a conventional saline or buffered aqueous solution medium in which the composition of the present invention is suspended or dissolved. In this form, the composition of the present invention can be conveniently used to prevent, improve or otherwise treat infection. After introduction into the host, the vaccine can elicit an immune response including, but not limited to, the production of antibodies and / or cytokines and / or activation of CD8+T cells, antigen presenting cells, CD4+T cells, dendritic cells and / or other cellular responses.
[0074] As used herein, the term "adjuvant" refers to a compound that, when used in combination with a specific immunogen in a formulation, enhances or otherwise changes or modifies the resulting immune response. Modification of the immune response includes strengthening or expanding the specificity of one or both of the antibody and cellular immune responses. Modification of the immune response can also mean reducing or suppressing certain antigen-specific immune responses.
[0075] A "costimulatory molecule" refers to a cognate binding partner on an immune cell (eg, a T cell) that specifically binds to a costimulatory ligand, thereby mediating a costimulatory response by the T cell, such as, but not limited to, proliferation.
[0076] Compositions and methods
[0077] Disclosed herein are a series of engineered mRNAs and methods for improving protein expression. In some aspects, disclosed herein is an engineered mRNA comprising: a first nucleic acid sequence comprising a RPS27A 5' untranslated region (5'UTR) sequence or an engineered 5' untranslated region (5'UTR) sequence; a second nucleic acid sequence comprising a heterologous nucleic acid sequence; and a third nucleic acid sequence comprising a RPS27A (3' untranslated region) 3'UTR sequence.
[0078] In some embodiments, the RPS27A 5′UTR sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, or SEQ ID NO: 11. In some embodiments, the RPS27A 5′UTR sequence is SEQ ID NO: 1. In some embodiments, the RPS27A 5′UTR sequence is SEQ ID NO: 2. In some embodiments, the RPS27A 5′UTR sequence is SEQ ID NO: 3. In some embodiments, the RPS27A 5′UTR sequence is SEQ ID NO: 4. In some embodiments, the RPS27A 5′UTR sequence is SEQ ID NO: 5. In some embodiments, the RPS27A 5′UTR sequence is SEQ ID NO: 6. In some embodiments, the RPS27A 5′UTR sequence is SEQ ID NO: 7. In some embodiments, the RPS27A 5'UTR sequence is SEQ ID NO: 8. In some embodiments, the RPS27A 5'UTR sequence is SEQ ID NO: 9. In some embodiments, the RPS27A 5'UTR sequence is SEQ ID NO: 10. In some embodiments, the RPS27A 5'UTR sequence is SEQ ID NO: 11.
[0079] In some embodiments, the RPS27A 5'UTR sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, or SEQ ID NO: 11, or a fragment or functionally active variant thereof.
[0080] In some embodiments, the RPS27A 5′UTR sequence is selected from the group comprising a nucleic acid sequence that is at least 60% (e.g., at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%) identical to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, or SEQ ID NO: 11.
[0081] In some embodiments, the RPS27A 3'UTR sequence is selected from the group consisting of SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 87, SEQ ID NO: 89, or SEQ ID NO: 91, or a fragment or functionally active variant thereof. In some embodiments, the RPS27A 3'UTR sequence is SEQ ID NO: 24. In some embodiments, the RPS27A 3'UTR sequence is SEQ ID NO: 25. In some embodiments, the RPS27A 3'UTR sequence is SEQ ID NO: 26. In some embodiments, the RPS27A 3'UTR sequence is SEQ ID NO: 87. In some embodiments, the RPS27A 3'UTR sequence is SEQ ID NO: 89. In some embodiments, the RPS27A 3'UTR sequence is SEQ ID NO: 91. In some embodiments, the RPS27A 3'UTR sequence of any preceding aspect comprises functional motif A, motif B and / or motif C, wherein functional motif A comprises SEQ ID NO:88, wherein functional motif B comprises SEQ ID NO:90, and wherein functional motif C comprises SEQ ID NO:92.
[0082] In some embodiments, the RPS27A 3′UTR sequence is selected from the group comprising a nucleic acid sequence that is at least 60% (e.g., at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%) identical to SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 87, SEQ ID NO: 89, or SEQ ID NO: 91.
[0083] In some embodiments, the heterologous nucleic acid sequence encodes a target protein.The heterologous nucleic acid sequence or target protein can be any nucleic acid sequence / protein of interest.
[0084] In some embodiments, the target protein is an immunotherapy protein. In some embodiments, the target protein is a co-stimulatory molecule. In some embodiments, the target protein is a genome editing enzyme or a nuclease. In some embodiments, the target protein is used in protein replacement therapy.
[0085] In some embodiments, the costimulatory molecule is selected from ICOS, CD28, CD27, HVEM, LIGHT, CD40L, 4-1BB, OX40, DR3, GITR, CD30, SLAM, CD2, CD226, galectin-9, TIM1, LFA1, B7-H2, B7-1, B7-2, CD70, LIGHT, HVEM, CD40, 4-1BBL, OX40L, TL1A, GITRL, CD30L, SLAM, CD48, CD58, CD155, CD112, CD80, CD86, ICOSL, TIM3, TIM4, ICAM1, or LFA3.
[0086] In some embodiments, the costimulatory molecule is ICOS. In some embodiments, the costimulatory molecule is CD28. In some embodiments, the costimulatory molecule is CD27. In some embodiments, the costimulatory molecule is HVEM. In some embodiments, the costimulatory molecule is LIGHT. In some embodiments, the costimulatory molecule is CD40L. In some embodiments, the costimulatory molecule is 4-1BB. In some embodiments, the costimulatory molecule is OX40. In some embodiments, the costimulatory molecule is DR2. In some embodiments, the costimulatory molecule is GITR. In some embodiments, the costimulatory molecule is CD30. In some embodiments, the costimulatory molecule is SLAM. In some embodiments, the costimulatory molecule is CD2. In some embodiments, the costimulatory molecule is CD226. In some embodiments, the costimulatory molecule is galectin 9. In some embodiments, the costimulatory molecule is TIM1. In some embodiments, the costimulatory molecule is LFA1. In some embodiments, the costimulatory molecule is B7-H2. In some embodiments, the costimulatory molecule is B7-1. In some embodiments, the costimulatory molecule is B7-2. In some embodiments, the costimulatory molecule is CD70. In some embodiments, the costimulatory molecule is LIGHT. In some embodiments, the costimulatory molecule is HVEM. In some embodiments, the costimulatory molecule is 4-1BBL. In some embodiments, the costimulatory molecule is OX40L. In some embodiments, the costimulatory molecule is TL1A. In some embodiments, the costimulatory molecule is GITRL. In some embodiments, the costimulatory molecule is CD30L. In some embodiments, the costimulatory molecule is CD48. In some embodiments, the costimulatory molecule is SLAM. In some embodiments, the costimulatory molecule is CD58. In some embodiments, the costimulatory molecule is CD155. In some embodiments, the costimulatory molecule is CD112. In some embodiments, the costimulatory molecule is CD80. In some embodiments, the costimulatory molecule is CD86. In some embodiments, the costimulatory molecule is ICOSL. In some embodiments, the costimulatory molecule is TIM3. In some embodiments, the costimulatory molecule is TIM4. In some embodiments, the costimulatory molecule is ICAM1. In some embodiments, the costimulatory molecule is LFA3.
[0087] Sequences of costimulatory molecules include, for example (for human sequences): ICOS (NCBI Reference Sequence: NM_012092.3), CD28 (NCBI Reference Sequence: NM_006139.4), CD27 (NCBI Reference Sequence: NM_001242.4), HVEM (NCBI Reference Sequence: NM_003820.3), LIGHT (NCBI Reference Sequence: NM_003807.4), CD40L (NCBI Reference Sequence: NM_000074.2), 4-1BB (NCBI Reference Sequence: NM_001561.5), OX40 (NCBI Reference Sequence: NM_00332. 7.4), DR3 (NCBI Reference Sequence: NM_148965.1), GITR (NCBI Reference Sequence: NM_004195.3), CD30 (GenBank: M83554.1), SLAM (NCBI Reference Sequence: NM_003037.4), CD2 (NCBI Reference Sequence: NM_001328609.1), CD226 (NCBI Reference Sequence: NM_006566.3), galectin-9 (GenBank: AB040130.2), TIM1 (GenBank: U02082.1), B7-H2 (NCBI Reference Sequence: NM_01 5259.5), B7-1 (NCBI Reference Sequence: NM_005191.4), B7-2 (NCBI Reference Sequence: NM_175862.5), CD70 (NCBI Reference Sequence: NM_001252.5), CD40 (NCBI Reference Sequence: NM_001250.5), 4-1BBL (NCBI Reference Sequence: NM_003811.4), OX40L (NCBI Reference Sequence: NM_003326.5), TL1A (NCBI Reference Sequence: NM_005118.4), GITRL (GenBank: AY358868.1), CD30L ... I reference sequence: NM_001244.3), SLAM (GenBank: U33017.1), CD48 (NCBI reference sequence: NM_001778.4), CD58 (NCBI reference sequence: NM_001779.3), CD155 (NCBI reference sequence: NM_006505.5), CD112 (NCBI reference sequence: NM_001042724.2), TIM3 (GenBank: AF450242.1), TIM4 (NCBI reference sequence: NM_138379.3), ICAM1 (NCBI reference sequence: NM_000201.3).
[0088] Thus, in some embodiments, the costimulatory molecules comprise ICOS (NCBI Reference Sequence: NM_012092.3), CD28 (NCBI Reference Sequence: NM_006139.4), CD27 (NCBI Reference Sequence: NM_001242.4), HVEM (NCBI Reference Sequence: NM_003820.3), LIGHT (NCBI Reference Sequence: NM_003807.4), CD40L (NCBI Reference Sequence: NM_000074.2), 4-1BB (NCBI Reference Sequence: NM_001561.5), OX40 (NCBI Reference Sequence: NM_00332 7.4), DR3 (NCBI Reference Sequence: NM_148965.1), GITR (NCBI Reference Sequence: NM_004195.3), CD30 (GenBank: M83554.1), SLAM (NCBI Reference Sequence: NM_003037.4), CD2 (NCBI Reference Sequence: NM_001328609.1), CD226 (NCBI Reference Sequence: NM_006566.3), galectin-9 (GenBank: AB040130.2), TIM1 (GenBank: U02082.1), B7-H2 (NCBI Reference Sequence: NM_001328609.1), and β-actin (GenBank: β-actin). 15259.5), B7-1 (NCBI Reference Sequence: NM_005191.4), B7-2 (NCBI Reference Sequence: NM_175862.5), CD70 (NCBI Reference Sequence: NM_001252.5), CD40 (NCBI Reference Sequence: NM_001250.5), 4-1BBL (NCBI Reference Sequence: NM_003811.4), OX40L (NCBI Reference Sequence: NM_003326.5), TL1A (NCBI Reference Sequence: NM_005118.4), GITRL (GenBank: AY358868.1), CD30L (N CBI reference sequence: NM_001244.3), SLAM (GenBank: U33017.1), CD48 (NCBI reference sequence: NM_001778.4), CD58 (NCBI reference sequence: NM_001779.3), CD155 (NCBI reference sequence: NM_006505.5), CD112 (NCBI reference sequence: NM_001042724.2), TIM3 (GenBank: AF450242.1), TIM4 (NCBI reference sequence: NM_138379.3), ICAM1 (NCBI reference sequence: NM_000201.3), or variants or fragments thereof that are at least 60% (e.g., at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%) identical to a nucleic acid sequence.
[0089] In some embodiments, the genome editing enzyme is selected from zinc finger nuclease (ZFN), transcription activator-like effector-based nuclease (TALEN), or clustered regularly interspaced short palindromic repeat (CRISPR) system nuclease. In some embodiments, the genome editing enzyme is Cpf1, or a variant or homolog thereof. In some embodiments, the genome editing enzyme is Cas9, or a variant or homolog thereof.
[0090] In some embodiments, the target protein comprises a fluorescent protein. In some embodiments, the target protein is fused to a fluorescent protein. In one embodiment, the fluorescent protein comprises mCherry (mCh). In some embodiments, the fluorescent protein comprises GFP. In some embodiments, the fluorescent protein comprises YFP.
[0091] In some embodiments, the target protein includes a viral protein. In some embodiments, the viral protein is a coronavirus protein. Coronaviruses constitute the Orthocoronavirinae subfamily in the Coronaviridae, Nidovirales, and Riboviria families. They are enveloped viruses with a positive-sense single-stranded RNA genome and a helical symmetrical nucleocapsid. The genome size of coronaviruses ranges from about 27 kilobases to 34 kilobases. The structure of coronaviruses generally consists of the following: spike protein, hemagglutinin-esterease dimer (HE), membrane glycoprotein (M), envelope protein (E), nucleocapsid protein (N), and RNA. The Coronaviridae family includes genera including, for example, alphacoronavirus (e.g., human coronavirus 229E, human coronavirus NL63, long-winged bat coronavirus 1, long-winged bat coronavirus HKU8, porcine epidemic diarrhea virus, horseshoe bat coronavirus HKU2, high-headed bat coronavirus 512), betacoronavirus (e.g., COVID-19, betacoronavirus 1, human coronavirus HKU1, mouse coronavirus, scutellaria bat coronavirus HKU5, fruit bat coronavirus HKU9, severe acute respiratory syndrome-related coronavirus, flat-headed bat coronavirus HKU4, Middle East respiratory syndrome-related coronavirus (MERS), human coronavirus OC43, hedgehog coronavirus 1 (EriCoV)), gammacoronavirus (e.g., beluga whale coronavirus SW1, infectious bronchitis virus) and gammacoronavirus (e.g., nightingale coronavirus HKU11, porcine coronavirus HKU15). In some embodiments, the viral protein is a protein of a severe acute respiratory syndrome-related coronavirus. In some embodiments, the viral protein is a protein of a MERS coronavirus.
[0092] In some embodiments, the viral protein is a COVID-19 protein, including, for example, a COVID-19 spike protein, a COVID-19 envelope protein, a COVID-19 membrane protein, or a COVID-19 nucleocapsid protein, or fragments thereof. In some embodiments, the viral protein is the receptor binding domain of the COVID-19 spike protein.
[0093] In some embodiments, the target protein is factor IX. Factor IX is a human protein produced as a zymogen and is an inactive precursor (accession number: HGNC: 3551; Entrez Gene: 2158; Ensembl: ENSG00000101981; OMIM: 300746; UniProtKB: P00740). In some embodiments, the target protein is phenylalanine hydroxylase (accession number: HGNC: 8582; Entrez Gene: 5053; Ensembl: ENSG00000171759; OMIM: 612349; UniProtKB: P00439). In some embodiments, the target protein is CFTR. Other target proteins may include, but are not limited to, enzymes, enzyme cofactors, hormones, coagulation factors, cytokines, growth factors, and the like. For example, see US Pat. No. 10,071,114, which is incorporated herein by reference.
[0094] In some embodiments, the RPS27A 5′UTR sequence comprises SEQ ID NO: 2, and the RPS27A 3′UTR sequence comprises SEQ ID NO: 24. In some embodiments, the RPS27A 5′UTR sequence comprises SEQ ID NO: 3, and the RPS27A 3′UTR sequence comprises SEQ ID NO: 24. In some embodiments, the RPS27A 5′UTR sequence comprises SEQ ID NO: 84, and the RPS27A 3′UTR sequence comprises SEQ ID NO: 87.
[0095] In some embodiments, the engineered mRNA of any of the preceding aspects further comprises a 120A tail.
[0096] In some embodiments, the engineered mRNA of any of the aforementioned aspects comprises an RNA sequence selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, or SEQ ID NO: 40.
[0097] In some embodiments, the engineered mRNA of any of the preceding aspects comprises an RNA sequence selected from the group consisting of SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:97.
[0098] In some embodiments, the RPS27A 5'UTR sequence is a fragment of an endogenous (wild-type) RPS27A gene sequence. In some embodiments, the RPS27A 5'UTR sequence is a modified version of the RPS27A gene sequence (e.g., comprising nucleotide changes, insertions, deletions, etc.). In some embodiments, the RPS27A 3'UTR sequence is a fragment of an endogenous (wild-type) RPS27A gene sequence. In some embodiments, the RPS27A 3'UTR sequence is a modified version of the RPS27A gene sequence (e.g., comprising nucleotide changes, insertions, deletions, etc.).
[0099] In some embodiments, the engineered mRNA comprises a modified removal of a 5′ terminal oligopyrimidine tract (TOP). In some embodiments, the engineered mRNA comprises a modification of one or more upstream translation start codons.
[0100] In some embodiments, the engineered mRNA comprises a sequence for endoplasmic reticulum (ER) targeting of a target protein. In some embodiments, the engineered mRNA comprises a calnexin sequence (e.g., as disclosed in SEQ ID NO: 27 and SEQ ID NO: 28).
[0101] In some embodiments, the engineered mRNA comprises a sequence for mitochondrial targeting of a target protein.In some embodiments, the engineered mRNA comprises a TOM20 sequence (e.g., as disclosed in SEQ ID NO: 29 and SEQ ID NO: 30).
[0102] In some embodiments, the engineered mRNA comprises a sequence for lysosomal targeting of a target protein. In some embodiments, the engineered mRNA comprises a CaB sequence (e.g., as disclosed in SEQ ID NO: 31 and SEQ ID NO: 32).
[0103] In some embodiments, the engineered mRNA comprises a sequence for nuclear targeting of the target protein. In some embodiments, the engineered mRNA comprises a nuclear localization signal (NLS) sequence (e.g., as disclosed in SEQ ID NO: 33 and SEQ ID NO: 40).
[0104] In some aspects, disclosed herein is an engineered mRNA comprising: a first nucleic acid sequence comprising an engineered 5′ untranslated region (5′UTR) sequence; a second nucleic acid sequence comprising a heterologous nucleic acid sequence; and a third nucleic acid sequence comprising a RPS27A 3′ untranslated region (3′UTR) sequence.
[0105] In some embodiments, the engineered 5′UTR sequence is selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, or SEQ ID NO: 86.
[0106] In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 12. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 13. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 14. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 15. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 16. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 17. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 18. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 19. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 20. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 21. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 22. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 23.
[0107] In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 81. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 82. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 83. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 84. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 85. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 86.
[0108] In some embodiments, the engineered 5′UTR sequence is selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, or SEQ ID NO: 86, or a fragment or functionally active variant thereof.
[0109] In some embodiments, the engineered 5′UTR sequence is selected from the group consisting of a nucleic acid sequence that is at least 60% (e.g., at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%) identical to SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 85, or SEQ ID NO: 86.
[0110] In some embodiments, the engineered 5′UTR sequence comprises SEQ ID NO: 18, and the RPS27A 3′UTR sequence comprises SEQ ID NO: 24. In some embodiments, the engineered 5′UTR sequence comprises SEQ ID NO: 21, and the RPS27A 3′UTR sequence comprises SEQ ID NO: 24. In some embodiments, the engineered 5′UTR sequence comprises SEQ ID NO: 22, and the RPS27A 3′UTR sequence comprises SEQ ID NO: 24. In some embodiments, the engineered 5′UTR sequence comprises SEQ ID NO: 23, and the RPS27A 3′UTR sequence comprises SEQ ID NO: 24. In some embodiments, the engineered 5′UTR sequence comprises SEQ ID NO: 84, and the RPS27A 3′UTR sequence comprises SEQ ID NO: 24. In some embodiments, the engineered 5′UTR sequence comprises SEQ ID NO: 84, and the RPS27A 3′UTR sequence comprises SEQ ID NO: 87. In some embodiments, the engineered 5′UTR sequence comprises SEQ ID NO: 82, and the RPS27A 3′UTR sequence comprises SEQ ID NO: 24. In some embodiments, the engineered 5′UTR sequence comprises SEQ ID NO: 83, and the RPS27A 3′UTR sequence comprises SEQ ID NO: 24. In some embodiments, the engineered 5′UTR sequence comprises SEQ ID NO: 84, and the RPS27A 3′UTR sequence comprises SEQ ID NO: 89. In some embodiments, the engineered 5′UTR sequence comprises SEQ ID NO: 84, and the RPS27A 3′UTR sequence comprises SEQ ID NO: 91.
[0111] In some embodiments, expression of the target protein is increased by greater than about 10%, greater than about 20%, greater than about 30%, greater than about 40%, greater than about 50%, greater than about 60%, greater than about 70%, greater than about 80%, greater than about 90%, greater than about 100%, and more when operably linked to the RPS27A 5'UTR sequence and / or the RPS27A 3'UTR sequence, compared to a control (e.g., compared to the endogenous 5'UTR and / or 3'UTR of the target protein, or to additional 5'UTRs and / or 3'UTRs known in the art).
[0112] In some embodiments, expression of the target protein is increased by greater than about 10%, greater than about 20%, greater than about 30%, greater than about 40%, greater than about 50%, greater than about 60%, greater than about 70%, greater than about 80%, greater than about 90%, greater than about 100%, and more when operably linked to an engineered 5'UTR sequence and / or RPS27A 3'UTR sequence, compared to a control (e.g., compared to the endogenous 5'UTR and / or 3'UTR of the target protein, or to additional 5'UTRs and / or 3'UTRs known in the art).
[0113] In some aspects, disclosed herein is a vector comprising the engineered mRNA of any of the aforementioned aspects. In some embodiments, a cell comprises the vector of any of the aforementioned aspects. In some embodiments, the cell is from a group consisting of a mouse, a rat, a human, or a non-human primate. In some embodiments, the cell is from a mouse. In some embodiments, the cell is from a rat. In some embodiments, the cell is from a human. In some embodiments, the cell is from a non-human primate.
[0114] In some aspects, disclosed herein is a method of increasing protein expression, comprising the steps of introducing into a cell an engineered mRNA comprising: a first nucleic acid sequence comprising a RPS27A 5′UTR sequence; a second nucleic acid sequence comprising a heterologous nucleic acid sequence; and a third nucleic acid sequence comprising a RPS27A 3′UTR sequence.
[0115] In some embodiments, the RPS27A 5′UTR sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, or SEQ ID NO: 11. In some embodiments, the RPS27A 5′UTR sequence is SEQ ID NO: 1. In some embodiments, the RPS27A 5′UTR sequence is SEQ ID NO: 2. In some embodiments, the RPS27A 5′UTR sequence is SEQ ID NO: 3. In some embodiments, the RPS27A 5′UTR sequence is SEQ ID NO: 4. In some embodiments, the RPS27A 5′UTR sequence is SEQ ID NO: 5. In some embodiments, the RPS27A 5′UTR sequence is SEQ ID NO: 6. In some embodiments, the RPS27A 5′UTR sequence is SEQ ID NO: 7. In some embodiments, the RPS27A 5'UTR sequence is SEQ ID NO: 8. In some embodiments, the RPS27A 5'UTR sequence is SEQ ID NO: 9. In some embodiments, the RPS27A 5'UTR sequence is SEQ ID NO: 10. In some embodiments, the RPS27A 5'UTR sequence is SEQ ID NO: 11.
[0116] In some aspects, disclosed herein is a method of increasing protein expression, comprising the steps of introducing into a cell an engineered mRNA comprising: a first nucleic acid sequence comprising an engineered 5′UTR sequence; a second nucleic acid sequence comprising a heterologous nucleic acid sequence; and a third nucleic acid sequence comprising a RPS27A 3′UTR sequence.
[0117] In some embodiments, the engineered 5'UTR sequence is selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, or SEQ ID NO: 23. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 12. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 13. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 14. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 15. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 16. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 17. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 18. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 19. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 20. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 21. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 22. In some embodiments, the engineered 5'UTR sequence is SEQ ID NO: 23.
[0118] In some embodiments, the nucleic acid sequences disclosed herein are isolated. In some embodiments, the nucleic acid sequences disclosed herein are recombinant.
[0119] In some embodiments, the heterologous nucleic acid sequence encodes a target protein.The heterologous nucleic acid sequence or target protein can be any nucleic acid sequence / protein of interest.
[0120] In some embodiments, the target protein comprises a fluorescent protein. In some embodiments, the target protein is fused to a fluorescent protein. In one embodiment, the fluorescent protein comprises mCherry (mCh). In some embodiments, the fluorescent protein comprises GFP. In some embodiments, the fluorescent protein comprises YFP.
[0121] In some embodiments, the RPS27A 3'UTR sequence is selected from the group consisting of SEQ ID NO: 24, SEQ ID NO: 25, or SEQ ID NO: 26. In some embodiments, the RPS27A 3'UTR sequence is SEQ ID NO: 24. In some embodiments, the RPS27A 3'UTR sequence is SEQ ID NO: 25. In some embodiments, the RPS27A 3'UTR sequence is SEQ ID NO: 26.
[0122] In some aspects, disclosed herein is an engineered mRNA comprising: a first nucleic acid sequence comprising a RPS27A 5'UTR sequence; and a second nucleic acid sequence comprising a heterologous nucleic acid sequence. In some aspects, disclosed herein is an engineered mRNA comprising: a first nucleic acid sequence comprising an engineered 5'UTR sequence; and a second nucleic acid sequence comprising a heterologous nucleic acid sequence. In some aspects, disclosed herein is an engineered mRNA comprising: a nucleic acid sequence comprising a RPS27A 3'UTR sequence; and a second nucleic acid sequence comprising a heterologous nucleic acid sequence. These engineered mRNAs can be used in any of the vectors, cells, or methods described herein.
[0123] In embodiments herein, the RPS27A 5'UTR sequence is operably linked to a heterologous nucleic acid sequence. In embodiments herein, the engineered 5'UTR sequence is operably linked to a heterologous nucleic acid sequence. In embodiments herein, the RPS27A 3'UTR sequence is operably linked to a heterologous nucleic acid sequence.
[0124] In some embodiments, the nucleic acids disclosed herein (engineered mRNA) include at least one chemically modified nucleotide. In some embodiments, at least one chemically modified nucleotide includes a chemically modified core base, a chemically modified ribose, a chemically modified phosphodiester bond, or a combination thereof.
[0125] In one embodiment, the at least one chemically modified nucleotide is a chemically modified nucleobase.
[0126] In one embodiment, the chemically modified nucleobase is selected from 5-formylcytidine (5fC), 5-methylcytidine (5meC), 5-methoxycytidine (5moC), 5-hydroxycytidine (5hoC), 5-hydroxymethylcytidine (5hmC), 5-formyluridine (5fU), 5-methyluridine (5-meU), 5-methoxyuridine (5moU), 5-carboxymethyl ester uridine (5camU), pseudouridine (Ψ), N 1 -methyl pseudouridine (me 1 Ψ), N 6 -methyladenosine (me 6 A), or guanosine ( th G).
[0127] In some embodiments, the chemically modified nucleobase is 5-methoxyuridine (5moU). In some embodiments, the chemically modified nucleobase is pseudouridine (Ψ). In some embodiments, the chemically modified nucleobase is N1-methylpseudouridine (meth 1 Ψ).
[0128] The structures of these modified nucleobases are shown below:
[0129]
[0130] In one embodiment, at least one chemically modified nucleotide is a chemically modified ribose.
[0131] In one embodiment, the chemically modified ribose is selected from 2′-O-methyl (2′-O-Me), 2′-fluoro (2′-F), 2′-deoxy-2′-fluoro-β-D-arabinoic acid (2′F-ANA), 4′-S, 4′-SFANA, 2′-azido, UNA, 2′-O-methoxy-ethyl (2′-O-ME), 2′-O-allyl, 2′-O-ethylamine, 2′-O-cyanoethyl, locked nucleic acid (LAN), methylene-cLAN, N-MeO-amino BNA, or N-MeO-aminooxy BNA. In one embodiment, the chemically modified ribose is 2′-O-methyl (2′-O-Me). In one embodiment, the chemically modified ribose is 2′-fluoro (2′-F).
[0132] The structures of these modified ribose sugars are shown below:
[0133]
[0134] In one embodiment, at least one chemically modified nucleotide is a chemically modified phosphodiester bond.
[0135] In one embodiment, the chemically modified phosphodiester bond is selected from phosphorothioate (phosphorothioate, PS), boron phosphoroate, dithiophosphate (phosphodithioate, PS2), 3', 5'-amide, N3'-phosphoramidate (NP), phosphodiester (PO), or 2', 5'-phosphodiester (2', 5'-PO). In one embodiment, the chemically modified phosphodiester bond is phosphorothioate.
[0136] The structures of these modified phosphodiester bonds are shown below:
[0137]
[0138] In some embodiments, the heterologous nucleic acid sequence is heterologous to the 5'UTR sequence. In some embodiments, the heterologous nucleic acid sequence is heterologous to the 3'UTR sequence. In some embodiments, the heterologous nucleic acid sequence is heterologous to both the 5'UTR sequence and the 3'UTR sequence. In some aspects, disclosed herein is a vector comprising a nucleic acid encoding the engineered RNA of any of the aforementioned aspects. In some embodiments, the vector comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO: 41 to SEQ ID NO: 66.
[0139] In some aspects, disclosed herein is a cell comprising the engineered RNA or vector of any of the preceding aspects.
[0140] In some aspects, disclosed herein is a method of increasing protein expression, the method comprising the steps of:
[0141] Introducing into a cell an engineered mRNA comprising:
[0142] a first nucleic acid sequence comprising a RPS27A 5′UTR sequence or an engineered 5′ untranslated region (5′UTR) sequence;
[0143] a second nucleic acid sequence comprising a heterologous nucleic acid sequence; and
[0144] A third nucleic acid sequence comprises a RPS27A 3'UTR sequence.
[0145] In some aspects, disclosed herein is a vaccine for treating, preventing, reducing and / or inhibiting viral infection, comprising an engineered mRNA comprising:
[0146] a first nucleic acid sequence comprising a RPS27A 5′ untranslated region (5′UTR) sequence or an engineered 5′ untranslated region (5′UTR) sequence;
[0147] a second nucleic acid sequence comprising a heterologous nucleic acid sequence; and
[0148] A third nucleic acid sequence comprising a RPS27A 3' untranslated region (3'UTR) sequence, wherein the heterologous nucleic acid sequence encodes a viral protein.
[0149] In some embodiments, the viral protein is a COVID-19 protein, including, for example, a COVID-19 spike protein, a COVID-19 envelope protein, a COVID-19 membrane protein, or a COVID-19 nucleocapsid protein, or fragments thereof. In some embodiments, the viral protein is the receptor binding domain of the COVID-19 spike protein.
[0150] Thus, in some embodiments, the vaccine of any preceding aspect comprises an RNA sequence that is at least 60% (e.g., at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%) identical to SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, or SEQ ID NO: 97, or a functional fragment thereof. In some embodiments, the vaccine of any preceding aspect comprises an RNA sequence selected from the group consisting of SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, or SEQ ID NO: 97.
[0151] In some embodiments, the vaccine further comprises an adjuvant. In some embodiments, the vaccine further comprises a pharmaceutically acceptable carrier.
[0152] In some aspects, disclosed herein is a method of treating, preventing, reducing and / or inhibiting a viral infection in a subject, the method comprising administering to the subject an effective amount of the vaccine of any of the aforementioned aspects.
[0153] Example
[0154] The following examples are described below to illustrate compounds, systems, methods, and results according to the disclosed subject matter. These examples are not intended to be comprehensive, but rather to illustrate representative methods and results. These examples are not intended to exclude equivalents and variations of the present invention that would be apparent to one skilled in the art.
[0155] Example 1
[0156] In A549 and Hep3B cells, luciferase mRNAs with modified 5′ and 3′ UTRs from the mouse ribosomal protein S27a gene outperformed those with UTRs published in the literature. AG, AG+G, AG+G without a 3′ UTR, and CYBA are control luciferase mRNAs with the same coding sequence as the other engineered mRNAs. The 5′ and 3′ UTRs of AG are from the human α-globin gene (gene symbol: HBA1). AG+G is a modified AG with an extra G inserted at the end of the 5′ UTR to create a complete Kozak sequence (GCCACC). AG+G without a 3′ UTR has the same 5′ UTR as AG+G and has the 3′ UTR removed. CYBA has the 5′ and 3′ UTRs from the human cytochrome b-245α polypeptide gene (gene symbol: CYBA). All mRNAs were delivered using Lipofectamine 3000.
[0157] Example 2
[0158] eGFP mRNA with a non-native 5′UTR further enhanced protein expression in A549 cells, Hep3B cells, and 293T cells (n=2). AG+G and CYBA without a 3′UTR were control luciferase mRNAs as described in Example 1. All mRNAs were delivered by Lipofectamine 3000.
[0159] Example 3
[0160] Luciferase mRNA with 5UTR-18 and 3UTR-1 showed increased protein expression with pseudouridine modification (pU) in A549 cells compared to unmodified mRNA (n=3). All mRNAs were delivered by Lipofectamine 3000.
[0161] Example 4
[0162] Pseudouridine-modified luciferase mRNAs with 5UTR-22+3UTR-1 and 5UTR-23+3UTR-1 showed selective gene expression in a liver tumor cell line (Hep3B) compared to a lung tumor cell line (A549). All mRNAs were delivered by Lipofectamine 3000 (n=3).
[0163] Example 5
[0164] The organelle-targeted eGFP / mCherry mRNAs with 5'UTR and 3'UTR sequences disclosed herein can be used for organelle imaging in live Hep3B cells. The organelle imaging capabilities of these organelle-targeted eGFP / mCherry mRNAs were validated by colocalization with commercially available organelle imaging probes. All mRNAs were delivered using Lipofectamine 3000.
[0165] Example 6
[0166] Figure 6A and Figure 6B The results in Figure 2 were obtained in Hep3B cells and 293T cells, respectively. All mRNAs utilized the same 3′UTR: 3UTR1. All mRNAs were synthesized using pseudouridine to completely replace UTP during in vitro transcription. The mRNA with a 70nt 5′UTR showed the highest expression. AG+G and CYBA are control fluorescein mRNAs with previously published UTRs. The 5′UTR and 3′UTR of AG+G are from the human α-globin gene (gene symbol: HBA1), which has an extra G inserted at the end of the 5′UTR to create a complete Kozak sequence (GCCACC). CYBA has a 5′UTR and 3′UTR from the human cytochrome b-245α polypeptide gene (gene symbol: CYBA). All mRNAs were delivered by Lipofectamine 3000.
[0167] Example 7
[0168] Figure 7A and Figure 7B The results in Figure 2 were obtained in Hep3B cells and 293T cells, respectively. All mRNAs utilized the same 3′UTR: 3′UTR-1. All mRNAs were synthesized using pseudouridine to completely replace UTP during in vitro transcription. Removal of the microRNA target site in 5′UTR-18 produced 5′UTR-28. Removal of the microRNA target site in 5′UTR-25 produced 5′UTR-27. Removal of the microRNA target site in 5′UTR-26 produced 5′UTR-29. The mRNA with 5′UTR-27 showed the highest expression. AG+G and CYBA are control fluorescein mRNAs with previously published UTRs. The 5′UTR and 3′UTR of AG+G are derived from the human α-globin gene (gene symbol: HBA1), which has an extra G inserted at the end of the 5′UTR to create a complete Kozak sequence (GCCACC). CYBA has a 5′UTR and 3′UTR from the human cytochrome b-245α polypeptide gene (gene symbol: CYBA). All mRNAs were delivered by Lipofectamine 3000.
[0169] Example 8
[0170] Figure 8A and Figure 8B The results in the table were obtained in Hep3B cells and 293T cells, respectively. All mRNAs utilized the same 5′UTR: 5′UTR-27. Adding functional motif A to 3UTR-1 produced 3UTR-4. Adding functional motif B to 3UTR-1 produced 3UTR-5. Adding functional motif C to 3UTR-1 produced 3UTR-6. The mRNA with 3UTR-4 showed the highest expression. All mRNAs were synthesized using pseudouridine to completely replace UTP in in vitro transcription. AG+G and CYBA are control fluorescein mRNAs with previously published UTRs. The 5′UTR and 3′UTR of AG+G are from the human α-globin gene (gene symbol: HBA1), which has an extra G inserted at the end of the 5′UTR to create a complete Kozak sequence (GCCACC). CYBA has a 5′UTR and 3′UTR from the human cytochrome b-245α polypeptide gene (gene symbol: CYBA). All mRNAs were delivered by Lipofectamine 3000.
[0171] sequence
[0172] 5UTR-1(T44)
[0173] 5′UTR of transcript ENSMUST00000102844 from mouse ribosomal protein S27a gene (gene symbol: RPS27A)
[0174]
[0175]
[0176] 5UTR-2(T44-top)
[0177] Modification of 5UTR-1 by removal of the 5′ terminal oligopyrimidine tract (5′TOP)
[0178]
[0179] 5UTR-3(T44-top-uAUG)
[0180] Modification of 5UTR-2: The two upstream translation start codons AUG are modified to UAG
[0181]
[0182] 5UTR-4(truncated-T44-top-uAUG)
[0183] Modification of 5UTR-3 with the first 83 nucleotides after GGG truncation
[0184]
[0185] 5UTR-5(truncated-T44-top-uAUG-2AUG)
[0186] Modification of 5UTR-4 by adding an extra AUG before the AUG in the coding region, resulting in two tandem AUG translation start codons
[0187]
[0188] 5UTR-6(T45)
[0189] 5′UTR of transcript ENSMUST00000102845 from mouse ribosomal protein S27a gene (gene symbol: RPS27A)
[0190]
[0191] 5UTR-7(T45-top)
[0192] Modification of 5UTR-6 by removal of the 5′ terminal oligopyrimidine tract (5′TOP)
[0193]
[0194] 5UTR-8(T17)
[0195] 5′UTR of transcript ENST00000272317 from the human ribosomal protein S27a gene (gene symbol: RPS27A)
[0196]
[0197]
[0198] 5UTR-9(T 17-TOP)
[0199] Modification of 5UTR-8 by removal of the 5′ terminal oligopyrimidine tract (5′TOP)
[0200]
[0201] 5UTR-10(T35)
[0202] 5′UTR of transcript ENST00000404735 from the human ribosomal protein S27a gene (gene symbol: RPS27A)
[0203]
[0204] 5UTR-11(T35-TOP)
[0205] Modification of 5UTR-10 by removal of the 5′ terminal oligopyrimidine tract (5′TOP)
[0206]
[0207] 5UTR-12 (10nt)
[0208] 10nt non-native 5′UTR with GGG, Kozak sequence (GCCACC) and minimal secondary structure
[0209]
[0210] 5UTR-13 (20nt)
[0211] 20nt non-native 5′UTR with GGG, Kozak sequence (GCCACC) and minimal secondary structure
[0212]
[0213] 5UTR-14 (30nt)
[0214] 30nt non-native 5′UTR with GGG, Kozak sequence (GCCACC) and minimal secondary structure
[0215]
[0216] 5UTR-15 (40nt)
[0217] 40nt non-native 5′UTR with GGG, Kozak sequence (GCCACC) and minimal secondary structure
[0218]
[0219]
[0220] 5UTR-16 (50nt)
[0221] 50nt non-native 5′UTR with GGG, Kozak sequence (GCCACC) and minimal secondary structure
[0222]
[0223] 5UTR-17 (60nt)
[0224] 60nt non-native 5′UTR with GGG, Kozak sequence (GCCACC) and minimal secondary structure
[0225]
[0226] 5UTR-18 (70nt=0305K)
[0227] 70nt non-native 5′UTR with GGG, Kozak sequence (GCCACC) and minimal secondary structure
[0228]
[0229] 5UTR-19 (100nt)
[0230] 100nt non-native 5′UTR with GGG, Kozak sequence (GCCACC) and minimal secondary structure
[0231]
[0232] 5UTR-20 (50nt=0301K-1)
[0233] Alternative 50nt non-native 5′UTR with GGG, Kozak sequence (GCCACC) and minimal secondary structure
[0234]
[0235] 5UTR-21 (50nt=0301K-2)
[0236] Alternative 50nt non-native 5′UTR with GGG, Kozak sequence (GCCACC) and minimal secondary structure
[0237]
[0238] 5UTR-22 (70nt = 1015K-A)
[0239] A 70nt non-native 5′UTR with a G, Kozak sequence (GCCACC), minimal secondary structure, and modified ACGU content (25% GC, 27% A, 37% U)
[0240]
[0241] 5UTR-23 (70nt = 1015K-B)
[0242] A 70nt non-native 5′UTR with a G, Kozak sequence (GCCACC), minimal secondary structure, and modified ACGU content (25% GC, 17% A, 48% U)
[0243]
[0244] 3UTR-1(T44 / 45)
[0245] 3′UTR of transcripts ENSMUST00000102844 and ENSMUST00000102845 from the mouse ribosomal protein S27a gene (gene symbol: RPS27A)
[0246]
[0247] 3UTR-2(T35)
[0248] 3′UTR of transcript ENST00000404735 from the human ribosomal protein S27a gene (gene symbol: RPS27A)
[0249]
[0250] 3UTR-3(T17)
[0251] 3′UTR of transcript ENST00000272317 from the human ribosomal protein S27a gene (gene symbol: RPS27A)
[0252]
[0253] T44-TOP-uAUG-Calnexin-EGFP (eGFP mRNA targeted to the ER)
[0254]
[0255]
[0256]
[0257]
[0258] T44-TOP-uAUG-Calnexin-mCherry (mCherry mRNA targeted to the ER)
[0259]
[0260]
[0261]
[0262] T44-TOP-uAUG-TOM20-EGFP (eGFP mRNA targeted to mitochondria)
[0263]
[0264]
[0265] T44-TOP-uAUG-TOM20-mCherry (mCherry mRNA targeted to mitochondria)
[0266]
[0267]
[0268] T44-TOP-uAUG-CatB-EGFP (eGFP mRNA targeted to lysosomes)
[0269]
[0270]
[0271] T44-TOP-uAUG-CatB-mCherry (mCherry mRNA targeted to lysosomes)
[0272]
[0273]
[0274]
[0275] T44-top-uAUG-NLS-eGFP-NLS (eGFP mRNA targeted to the nucleus)
[0276]
[0277]
[0278] T44-top-uAUG-NLS-mCherry-NLS (mCherry mRNA targeted to the nucleus)
[0279]
[0280]
[0281] T44-TOP-uAUG-TOM20-mCherry-P2A-Calnexin-eGFP
[0282]
[0283]
[0284]
[0285]
[0286] T44-TOP-uAUG-TOM20-mCherry-P2A-CatB-eGFP
[0287]
[0288]
[0289]
[0290] T44-TOP-uAUG-TOM20-mCherry-P2A-NLS-eGFP-NLS
[0291]
[0292]
[0293] T44-TOP-uAUG-TOM20-mCherry-GGGGS4-calnexin-eGFP
[0294]
[0295]
[0296]
[0297] T44-TOP-uAUG-TOM20-mCherry-GGGGS4-CatB-eGFP
[0298]
[0299]
[0300]
[0301] T44-TOP-uAUG-TOM20-mCherry-GGGGS4-NLS-eGFP-NLS
[0302]
[0303] Note: In the translation of "GGGGS4-钙联蛋白", "钙联蛋白" is translated as "calnexin" according to common biological terms. If there are specific requirements for this term in your context, it may need to be adjusted accordingly.
[0304] This article also discloses a DNA sequence targeting the above RNA sequence:
[0305] 5UTR-1(T44)
[0306] 5′UTR of transcript ENSMUST00000102844 from mouse ribosomal protein S27a gene (gene symbol: RPS27A)
[0307]
[0308] 5UTR-2(T44-top)
[0309] Modification of 5UTR-1 by removal of the 5′ terminal oligopyrimidine tract (5′TOP)
[0310]
[0311] 5UTR-3(T44-top-uATG)
[0312] Modification of 5UTR-2: The two upstream translation start codons ATG are modified to TAG
[0313]
[0314] 5UTR-4(truncated-T44-top-uATG)
[0315] Modification of 5UTR-3 with the first 83 nucleotides after GGG truncation
[0316]
[0317] 5UTR-5(truncated-T44-top-uATG-2ATG)
[0318] Modification of 5UTR-4 by adding an extra ATG before the ATG in the coding region, resulting in two tandem ATG translation start codons
[0319]
[0320] 5UTR-6(T45)
[0321] 5′UTR of transcript ENSMUST00000102845 from mouse ribosomal protein S27a gene (gene symbol: RPS27A)
[0322]
[0323] 5UTR-7(T45-top)
[0324] Modification of 5UTR-6 by removal of the 5′ terminal oligopyrimidine tract (5′TOP)
[0325]
[0326] 5UTR-8(T17)
[0327] 5′UTR of transcript ENST00000272317 from the human ribosomal protein S27a gene (gene symbol: RPS27A)
[0328]
[0329] 5UTR-9(T17-TOP)
[0330] Modification of 5UTR-8 by removal of the 5′ terminal oligopyrimidine tract (5′TOP)
[0331]
[0332] 5UTR-10(T35)
[0333] 5′UTR of transcript ENST00000404735 from the human ribosomal protein S27a gene (gene symbol: RPS27A)
[0334]
[0335] 5UTR-11(T35-TOP)
[0336] Modification of 5UTR-10 by removal of the 5′ terminal oligopyrimidine tract (5′TOP)
[0337]
[0338] 5UTR-12 (10nt)
[0339] 10nt non-native 5′UTR with GGG, Kozak sequence (GCCACC) and minimal secondary structure
[0340]
[0341] 5UTR-13 (20nt)
[0342] 20nt non-native 5′UTR with GGG, Kozak sequence (GCCACC) and minimal secondary structure
[0343]
[0344] 5UTR-14 (30nt)
[0345] 30nt non-native 5′UTR with GGG, Kozak sequence (GCCACC) and minimal secondary structure
[0346] GGGAAAGAAACAGGACAGAAAACAGCCACC (SEQ ID NO: 54)
[0347] 5UTR-15 (40nt)
[0348] 40nt non-native 5′UTR with GGG, Kozak sequence (GCCACC) and minimal secondary structure
[0349]
[0350]
[0351] 5UTR-16 (50nt)
[0352] 50nt non-native 5′UTR with GGG, Kozak sequence (GCCACC) and minimal secondary structure
[0353]
[0354] 5UTR-17 (60nt)
[0355] 60nt non-native 5′UTR with GGG, Kozak sequence (GCCACC) and minimal secondary structure
[0356]
[0357] 5UTR-18 (70nt=0305K)
[0358] 70nt non-native 5′UTR with GGG, Kozak sequence (GCCACC) and minimal secondary structure
[0359]
[0360] 5UTR-19 (100nt)
[0361] 100nt non-native 5′UTR with GGG, Kozak sequence (GCCACC) and minimal secondary structure
[0362]
[0363] 5UTR-20 (50nt=0301K-1)
[0364] Alternative 50nt non-native 5′UTR with GGG, Kozak sequence (GCCACC) and minimal secondary structure
[0365]
[0366] 5UTR-21 (50nt=0301K-2)
[0367] Alternative 50nt non-native 5′UTR with GGG, Kozak sequence (GCCACC) and minimal secondary structure
[0368]
[0369] 5UTR-22 (70nt = 1015K-A)
[0370] A 70nt non-native 5′UTR with a G, Kozak sequence (GCCACC), minimal secondary structure, and modified ACGU content (25% GC, 27% A, 37% U)
[0371]
[0372] 5UTR-23 (70nt = 10 15K-B)
[0373] A 70nt non-native 5′UTR with a G, Kozak sequence (GCCACC), minimal secondary structure, and modified ACGU content (25% GC, 17% A, 48% U)
[0374]
[0375] 3UTR-1(T44 / 45)
[0376] 3′UTR of transcripts ENSMUST00000102844 and ENSMUST00000102845 from the mouse ribosomal protein S27a gene (gene symbol: RPS27A)
[0377]
[0378] 3UTR-2(T35)
[0379] 3′UTR of transcript ENST00000404735 from the human ribosomal protein S27a gene (gene symbol: RPS27A)
[0380]
[0381] 3UTR-3(T17)
[0382] 3′UTR of transcript ENST00000272317 from the human ribosomal protein S27a gene (gene symbol: RPS27A)
[0383]
[0384] T44-TOP-uATG-Calnexin-EGFP (eGFP mRNA targeted to the ER)
[0385]
[0386]
[0387]
[0388] T44-TOP-uATG-Calnexin-mCherry (mCherry mRNA targeted to the ER)
[0389]
[0390]
[0391]
[0392] T44-TOP-uATG-TOM20-EGFP (eGFP mRNA targeted to mitochondria)
[0393]
[0394] T44-TOP-uATG-TOM20-mCherry (mCherry mRNA targeted to mitochondria)
[0395]
[0396] T44-TOP-uATG-CatB-EGFP (eGFP mRNA targeted to lysosomes)
[0397]
[0398]
[0399]
[0400] T44-TOP-uATG-CatB-mCherry (mCherry mRNA targeted to lysosomes)
[0401]
[0402]
[0403] T44-top-uATG-NLS-eGFP-NLS (eGFP mRNA targeted to the nucleus)
[0404]
[0405] T44-top-uATG-NLS-mCherry-NLS (mCherry mRNA targeted to the nucleus)
[0406]
[0407]
[0408] T44-TOP-uATG-TOM20-mCherry-P2A-Calnexin-eGFP
[0409]
[0410]
[0411]
[0412]
[0413] T44-TOP-uATG-TOM20-mCherry-P2A-CatB-eGFP
[0414]
[0415]
[0416]
[0417] T44-TOP-uATG-TOM20-mCherry-P2A-NLS-eGFP-NLS
[0418]
[0419]
[0420]
[0421] T44-TOP-uATG-TOM20-mCherry-GGGGS4-Calnexin-eGFP
[0422]
[0423]
[0424]
[0425] T44-TOP-uATG-TOM20-mCherry-GGGGS4-CatB-eGFP
[0426]
[0427]
[0428]
[0429]
[0430] T44-TOP-uATG-TOM20-mCherry-GGGGS4-NLS-eGFP-NLS
[0431]
[0432]
[0433] 5UTR-24
[0434] 90nt non-native 5′UTR with GGG, Kozak sequence (GCCACC) and minimal secondary structure
[0435]
[0436] 5UTR-25
[0437] A 70nt non-native 5'UTR with GG, a Kozak sequence (GCCACC), minimal secondary structure, and modified nucleotide composition.
[0438]
[0439] 5UTR-26
[0440] A 70nt non-native 5'UTR with GG, a Kozak sequence (GCCACC), minimal secondary structure, and modified nucleotide composition.
[0441]
[0442] 5UTR-27
[0443] A non-natural 5'UTR having the same length and nucleotide composition as 5UTR-25 without a microRNA target site in 5UTR-25.
[0444]
[0445] 5UTR-28
[0446] A non-natural 5′UTR having the same length and nucleotide composition as 5UTR-18 without a microRNA target site in 5UTR-18.
[0447]
[0448] 5UTR-29
[0449] A non-natural 5'UTR having the same length and nucleotide composition as 5UTR-26 without a microRNA target site in 5UTR-26.
[0450]
[0451] 3UTR-4
[0452] Modified 3UTR-1 with functional motif A (underlined) appended to the 3' end.
[0453]
[0454] Motif A
[0455]
[0456] 3UTR-5
[0457] Modified 3UTR-1 with functional motif B (underlined) appended to the 3' end.
[0458]
[0459] Motif B
[0460]
[0461] 3UTR-6
[0462] Modified 3UTR-1 with functional motif C (underlined) appended to the 3' end.
[0463]
[0464] Motif C
[0465]
[0466] COVID-19 mRNA Vaccine1
[0467] The full-length sequence of the mRNA expressing the coronavirus (COVID-19) spike protein as an antigen using 5UTR-27, 3UTR-4, and 120A tail (SEQ ID NO: 93)
[0468]
[0469]
[0470]
[0471]
[0472] COVID-19 mRNA Vaccine 2
[0473] Full-length sequence of mRNA expressing the coronavirus (COVID-19) receptor binding domain (RBD) of the spike protein as an antigen using 5UTR-27, 3UTR-4, and 120A tail (SEQ ID NO: 94)
[0474]
[0475]
[0476] COVID-19 mRNA Vaccine 3
[0477] The full-length sequence of mRNA expressing the coronavirus (COVID-19) envelope protein as an antigen using 5UTR-27, 3UTR-4, and 120A tail (SEQ ID NO: 95)
[0478]
[0479]
[0480] COVID-19 mRNA Vaccine4
[0481] The full-length sequence of mRNA expressing coronavirus (COVID-19) membrane protein as antigen using 5UTR-27, 3UTR-4 and 120A tail (SEQ ID NO: 96)
[0482]
[0483]
[0484] COVID-19 mRNA Vaccine5
[0485] The full-length sequence of mRNA expressing coronavirus (COVID-19) nucleocapsid protein as antigen using 5UTR-27, 3UTR-4 and 120A tail (SEQ ID NO: 97)
[0486]
[0487]
[0488]
[0489] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosed invention belongs. Publications cited herein and the materials for which they are cited are expressly incorporated by reference.
[0490] Those skilled in the art will appreciate that various changes and modifications may be made to the preferred embodiments of the present invention, and that these changes and modifications may be made without departing from the spirit of the present invention. Therefore, the appended claims are intended to encompass all such equivalent variations that fall within the true spirit and scope of the present invention.
Claims
1. An engineered mRNA, wherein the engineered mRNA consists of: a first nucleic acid sequence, wherein the first nucleic acid sequence consists of an engineered 5' untranslated region (5'UTR) sequence; a second nucleic acid sequence, wherein the second nucleic acid sequence consists of a heterologous nucleic acid sequence; and a third nucleic acid sequence, wherein the third nucleic acid sequence consists of a RPS27A 3' untranslated region (3'UTR) sequence; wherein the 5'UTR sequence is selected from the group consisting of: SEQ ID NO:82, SEQ ID NO:83 or SEQ ID NO:84; and Wherein the RPS27A 3'UTR sequence is selected from the group consisting of SEQ ID NO:24, SEQ ID NO:87, SEQ ID NO:89, or SEQ ID NO:
91.
2. The engineered mRNA of claim 1, wherein the heterologous nucleic acid sequence encodes a target protein.
3. The engineered mRNA of claim 2, wherein the target protein comprises a fluorescent protein.
4. The engineered mRNA of claim 3, wherein the fluorescent protein comprises GFP or mCherry.
5. The engineered mRNA of claim 2, wherein the target protein comprises a viral protein.
6. The engineered mRNA of claim 5, wherein the viral protein is a COVID-19 protein.
7. The engineered mRNA of claim 2, wherein the target protein comprises a co-stimulatory molecule.
8. The engineered mRNA of claim 7, wherein the co-stimulatory molecule is selected from ICOS, CD28, CD27, HVEM, LIGHT, CD40L, 4-1BB, OX40, DR3, GITR, CD30, SLAM, CD2, CD226, galectin 9, TIM1, LFA1, B7-H2, B7-1, B7-2, CD70, LIGHT, HVEM, CD40, 4-1BBL, OX40L, TL1A, GITRL, CD30L, SLAM, CD48, CD58, CD155, CD112, CD80, CD86, ICOSL, TIM3, TIM4, ICAM1, or LFA3.
9. The engineered mRNA of claim 1, comprising an RNA sequence selected from the group consisting of SEQ ID NO: 93, SEQ ID NO: 94, SEQ ID NO: 95, SEQ ID NO: 96, or SEQ ID NO:
97.
10. The engineered mRNA of claim 1, wherein the engineered mRNA comprises at least one chemically modified nucleotide.
11. The engineered mRNA of claim 10, wherein the at least one chemically modified nucleotide is a chemically modified nucleobase.
12. The engineered mRNA of claim 11, wherein the chemically modified nucleobase is pseudouridine.
13. A vector comprising a nucleic acid encoding the engineered mRNA of any one of claims 1 to 12. A cell comprising the vector according to claim 13 .
15. A method for increasing protein expression, the method comprising: The following steps are involved: Introducing engineered mRNA into cells, wherein the engineered mRNA consists of: a first nucleic acid sequence, wherein the first nucleic acid sequence consists of an engineered 5' untranslated region (5'UTR) sequence; a second nucleic acid sequence, wherein the second nucleic acid sequence consists of a heterologous nucleic acid sequence; and A third nucleic acid sequence, wherein the third nucleic acid sequence consists of a RPS27A 3'UTR sequence; wherein the 5'UTR sequence is selected from the group consisting of: SEQ ID NO:82, SEQ ID NO:83 or SEQ ID NO:84; and Wherein the RPS27A 3'UTR sequence is selected from the group consisting of SEQ ID NO:24, SEQ ID NO:87, SEQ ID NO:89, or SEQ ID NO:
91.
16. The method of claim 15, wherein the heterologous nucleic acid sequence encodes a target protein.
17. The method of claim 16, wherein the target protein comprises a fluorescent protein.
18. The method of claim 17, wherein the fluorescent protein comprises GFP or mCherry.
19. The method of claim 18, wherein the target protein comprises a viral protein.
20. The method of claim 19, wherein the viral protein is a COVID-19 protein.
21. The method of claim 16, wherein the target protein comprises a co-stimulatory molecule.
22. The method of claim 21, wherein the co-stimulatory molecule is selected from ICOS, CD28, CD27, HVEM, LIGHT, CD40L, 4-1BB, OX40, DR3, GITR, CD30, SLAM, CD2, CD226, galectin 9, TIM1, LFA1, B7-H2, B7-1, B7-2, CD70, LIGHT, HVEM, CD40, 4-1BBL, OX40L, TL1A, GITRL, CD30L, SLAM, CD48, CD58, CD155, CD112, CD80, CD86, ICOSL, TIM3, TIM4, ICAM1 or LFA3.
23. The method of claim 15, wherein the engineered mRNA comprises an RNA sequence selected from the group consisting of SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, or SEQ ID NO:
97.
24. The method of claim 15, wherein the engineered mRNA comprises at least one chemically modified nucleotide.
25. The method of claim 24, wherein the at least one chemically modified nucleotide is a chemically modified nucleobase.
26. The method of claim 25, wherein the chemically modified nucleobase is pseudouridine.
